Company Overview

Telo Genomics Corp. is a Canada-based biotechnology company focused on the development and commercialization of proprietary genomic technologies designed to measure telomere structure as a biomarker for disease risk, diagnosis, and prognosis. The company operates primarily in the biotechnology, molecular diagnostics, and precision medicine industries, with an emphasis on oncology and age-related diseases. Its core value proposition is the use of advanced three-dimensional telomere profiling to provide clinically actionable insights that are not captured by traditional telomere length measurements.

The company’s primary technology platform, TeloView®, is designed to analyze telomere architecture at the individual cell level, supporting applications in cancer prognosis, disease stratification, and drug development. Telo Genomics targets clinical laboratories, pharmaceutical and biotechnology companies, and academic research institutions as its main customer segments. Founded in the early 2010s as a spin-out from academic research, the company has evolved from a research-focused enterprise into a clinical-stage diagnostics company pursuing regulatory validation and commercial partnerships. Data inconclusive based on available public sources regarding the precise timing of all historical milestones.

Business Operations

Telo Genomics generates revenue primarily through research-use-only services, technology licensing, collaborative research agreements, and early-stage diagnostic development programs. Its operations are organized around its proprietary TeloView® Platform, which integrates imaging, software analytics, and proprietary algorithms to assess telomere organization. The company’s activities include assay development, validation studies, and collaborative clinical research in oncology indications such as prostate cancer and hematological malignancies.

Operations are primarily based in Canada, with laboratory and research functions supported by collaborations in the United States and Europe. The company controls its core intellectual property related to telomere profiling and image-based genomic analysis. Telo Genomics maintains relationships with academic institutions and clinical research organizations, though publicly disclosed joint ventures or majority-owned operating subsidiaries beyond its core corporate entity are limited. Data inconclusive based on available public sources regarding material revenue contribution by specific partnerships.

Strategic Position & Investments

Strategically, Telo Genomics positions itself as a differentiated biomarker company addressing unmet needs in cancer prognosis and patient stratification. Its growth initiatives focus on expanding clinical validation of TeloView®, advancing regulatory pathways for diagnostic use, and deepening partnerships with pharmaceutical companies seeking predictive biomarkers for clinical trials. The company has publicly emphasized precision oncology and early disease detection as long-term strategic priorities.

The company has historically invested in internal research and development rather than large-scale acquisitions. No material acquisitions of other operating companies have been consistently reported across multiple public disclosures. Telo Genomics’ strategy includes participation in emerging areas such as liquid biopsy applications and AI-enabled image analysis, though the commercial readiness of these initiatives remains under evaluation. Data inconclusive based on available public sources regarding the scale and timing of future capital investments.

Geographic Footprint

Telo Genomics is headquartered in Canada, with its primary corporate and research operations located in British Columbia. The company maintains a market presence in North America, supported by collaborations and research activities in the United States, which represents a key target market for future clinical adoption and commercialization.

Internationally, the company has engaged with research and clinical partners in Europe and Asia-Pacific regions on a limited basis, primarily through academic and translational research collaborations. While global in strategic intent, the company’s operational footprint outside North America remains modest, with international influence driven more by intellectual property licensing and collaborative research than by direct physical infrastructure.

Leadership & Governance

Telo Genomics was founded by scientists with expertise in telomere biology, leveraging decades of academic research into chromosomal architecture. The leadership team combines scientific, clinical, and capital markets experience, reflecting the company’s dual focus on research innovation and public company governance.

Key executives include:

• Har Deol – Chief Executive Officer
• Dr. Thomas J. Keefe – Chief Scientific Officer
• Dr. Alexander P. G. O’Connell – Chief Medical Officer
• Walt A. Miller – Chief Financial Officer

The leadership philosophy emphasizes scientific rigor, clinical validation, and disciplined capital allocation, with a strategic vision centered on establishing telomere-based biomarkers as a standard tool in precision medicine. The board of directors provides oversight with experience spanning biotechnology commercialization, diagnostics, and public market governance.